N
NextPoint Therapeutics
MPM Capital founded NextPoint Therapeutics, assembling a team of drug developers to create a strategic pipeline of immunotherapies based on a novel checkpoint axis discovered by our scientist founders
About NextPoint Therapeutics
NextPoint Therapeutics is a biotechnology startup that operates in the field of immuno-oncology. The company is focused on developing innovative therapies for cancer patients who do not respond to traditional PD-1/L1 inhibitors. The core of their work revolves around the novel HHLA2 pathway, a promising area in cancer treatment research.
Read full description
The company's business model is centered on the research, development, and eventual commercialization of these new therapies. Their primary source of revenue will likely come from the sale of these therapies once they have been approved for use in the medical field.
NextPoint's team is composed of experienced drug developers and renowned scientific founders, including XingXing Zang, PhD from the Albert Einstein College of Medicine, and Gordon Freeman, PhD from the Dana-Farber Cancer Institute. Their combined expertise forms the backbone of the company's research and development efforts.
The company has recently made significant strides in its work. In August 2023, they announced the first patient dosed in a Phase 1a/b clinical trial of NPX267, a novel therapeutic targeting KIR3DL3 to reactivate exhausted T and NK cells in HHLA2+ solid tumors.
NextPoint Therapeutics is also backed by substantial financial support. In January 2023, the company announced an $80 million Series B financing round co-led by Leaps by Bayer and Sanofi Ventures.
In summary, NextPoint Therapeutics is a promising startup in the immuno-oncology field, with a focus on developing innovative therapies for cancer patients who do not respond to traditional treatments.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Cambridge, United States
- Employees
- 38
- Open positions
- None listed
- Dealroom signal
- 33.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning NextPoint Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Feb 2024 | $42M | $400M | Undisclosed | ↗ |
| SERIES BOther financing | Jun 2023 | $80M | $320M | Invus · MPM BioImpact · Sixty Degree Capital · Binney Street Capital | ↗ |
Growth signals
Latest recorded traffic for NextPoint Therapeutics is 2.1K monthly website visits, up 500% over the last three months. NextPoint Therapeutics's team grew 8.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Sanofi Ventures
Leaps by Bayer
Invus
MPM BioImpact
Sixty Degree Capital
Binney Street Capital- PPPagodaTree Partners
- GFGordon Freeman
Catalio Capital Management
Other known investors1 additional known investor
University of Michigan
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NextPoint Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NextPoint Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.